- Home
- RMTI vs ACET Comparison
RMTI vs ACET Comparison
Compare RMTI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- ACET
- Stock Information
- Founded
- RMTI 1994
- ACET 1947
- Country
- RMTI United States
- ACET United States
- Employees
- RMTI N/A
- ACET N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- ACET Health Care
- Exchange
- RMTI Nasdaq
- ACET Nasdaq
- Market Cap
- RMTI 72.7M
- ACET 75.6M
- IPO Year
- RMTI 1998
- ACET N/A
- Fundamental
- Price
- RMTI $2.18
- ACET $0.92
- Analyst Decision
- RMTI Strong Buy
- ACET Strong Buy
- Analyst Count
- RMTI 2
- ACET 4
- Target Price
- RMTI $6.00
- ACET $5.67
- AVG Volume (30 Days)
- RMTI 309.2K
- ACET 455.3K
- Earning Date
- RMTI 11-12-2024
- ACET 11-06-2024
- Dividend Yield
- RMTI N/A
- ACET N/A
- EPS Growth
- RMTI N/A
- ACET N/A
- EPS
- RMTI N/A
- ACET N/A
- Revenue
- RMTI $98,917,000.00
- ACET N/A
- Revenue This Year
- RMTI $22.58
- ACET N/A
- Revenue Next Year
- RMTI N/A
- ACET N/A
- P/E Ratio
- RMTI N/A
- ACET N/A
- Revenue Growth
- RMTI 22.37
- ACET N/A
- 52 Week Low
- RMTI $1.16
- ACET $0.81
- 52 Week High
- RMTI $5.15
- ACET $3.62
- Technical
- Relative Strength Index (RSI)
- RMTI 49.23
- ACET 45.27
- Support Level
- RMTI $2.08
- ACET $0.85
- Resistance Level
- RMTI $2.41
- ACET $0.95
- Average True Range (ATR)
- RMTI 0.11
- ACET 0.08
- MACD
- RMTI 0.03
- ACET 0.00
- Stochastic Oscillator
- RMTI 47.73
- ACET 25.87
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.